Company: BDRX
Filing Date: 2025-05-12
Form Type: 424B3
Source: 0001214659-25-007341
Chunk: 5

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-05-12
Form: 424B3
Chunk 5
---
 2 |

The change in the number of
Ordinary Shares resulting from the reverse stock split and change in the number of Depositary Shares (and the underlying Ordinary Shares)
resulting from the change in ratio, including any changes resulting from fractional Depositary Shares not being issued to holders in connection
with the Depositary Share ratio change, has been applied retroactively to all share and per share amounts presented in this prospectus,
to the extent applicable. As a result of retroactively applying changes resulting from fractional Depositary Shares not being issued to
holders in connection with the Depositary Share ratio change, the amount of Ordinary Shares issued in prior transactions may not equal
the amount of Depositary Shares such Depositary Shares are currently exercisable for.

<div align='center'>MARKET AND INDUSTRY DATA</div>

Market data and certain industry
data and forecasts used throughout this prospectus were obtained from sources we believe to be reliable, including market research databases,
publicly available information, reports of governmental agencies, and industry publications and surveys. We have relied on certain data
from third-party sources, including internal surveys, industry forecasts, and market research, which we believe to be reliable based on
our management's knowledge of the industry. While we are not aware of any misstatements regarding the industry data presented in this
prospectus, our estimates involve risks and uncertainties and are subject to change based on various factors, including those discussed
under the heading “Risk Factors” and elsewhere in this prospectus.

Solely
for convenience, the trademarks and trade names in this prospectus may be referred to without the ® and ™ symbols, but such
references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable
law, their rights thereto. The trademarks, trade names and service marks in this prospectus are the property of their respective owners.

| 3 |

<div align='center'>PROSPECTUS SUMMARY</div>

This summary highlights selected information that is presented in greater detail elsewhere in this prospectus. This summary does not contain all of the information that may be important to you. You should carefully read this prospectus, including the documents incorporated by reference, which are described under “Where You Can Find Additional Information” and “Incorporation of Certain Information by Reference” in this prospectus. You should also carefully consider the matters discussed in the section in this prospectus entitled “Risk Factors.”

Our Business

We are a clinical stage biopharm